Ann Rheum Dis 2000;59(Suppl 1):i46-i49 ( November )

Article

Etanercept (Enbrel): update on therapeutic use George Spencer-Green

Immunex Corporation, 51 University Street, Seattle, WA 98101, USA

Correspondence to: Dr Spencer-Green (spencerg{at}immunex.com)

Tumour necrosis factor (TNF) is an important inflammatory disease mediator in a wide spectrum of articular diseases, including adult and juvenile rheumatoid arthritis (RA, JRA). Etanercept (Enbrel), approved in the United States and in Europe for use in patients with RA and JRA, is an effective inhibitor of TNF that has been shown to provide rapid and sustained improvement in both of these diseases. Long term studies continue to show that etanercept controls signs and symptoms of RA and JRA with no change in rate or type of adverse event over time. To demonstrate that etanercept is effective as first line treatment for patients with early active RA who have not been previously treated with methotrexate, and to examine the effect of etanercept on radiographic progression, a double blind, placebo controlled study was recently conducted, comparing etanercept with methotrexate (median dose 20 mg per week). Both etanercept 25 mg twice weekly and rapidly escalated methotrexate were effective in reducing the signs and symptoms of RA, and etanercept was significantly better than methotrexate in slowing the rate of radiographic erosions. In patients with severe psoriatic arthritis (PsA), a double blind, placebo controlled study demonstrated that etanercept was also effective in reducing disease activity in PsA. Etanercept has been well tolerated in all of these clinical trials and offers an important new treatment option to patients with inflammatory articular diseases.

---

© 2000 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Prince, F H M, Twilt, M, Cate, R t., van Rossum, M A J, Armbrust, W, Hoppenreijs, E P A H, van Santen-Hoeufft, M, Koopman-Keemink, Y, Wulffraat, N M, van Suijlekom-Smit, L W A (2009). Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68: 635-641 [Abstract] [Full Text]  
• Bonilla, E, Lee, Y Y, Phillips, P E, Perl, A (2007). Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis 66: 1688-1688 [Full Text]  
• Liew, F Y, Wei, X-Q, McInnes, I B (2003). Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis 62: ii48-50 [Full Text]  
• Amano, T., Yamasaki, S., Yagishita, N., Tsuchimochi, K., Shin, H., Kawahara, K.-i., Aratani, S., Fujita, H., Zhang, L., Ikeda, R., Fujii, R., Miura, N., Komiya, S., Nishioka, K., Maruyama, I., Fukamizu, A., Nakajima, T. (2003). Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes Dev. 17: 2436-2449 [Abstract] [Full Text]  
• Terslev, L, Torp-Pedersen, S, Qvistgaard, E, Kristoffersen, H, Rogind, H, Danneskiold-Samsoe, B, Bliddal, H (2003). Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 62: 178-181 [Abstract] [Full Text]  
• Kietz, D A, Pepmueller, P H, Moore, T L (2002). Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61: 171-173 [Abstract] [Full Text]